IV Insulin Therapy Developer Defends Diabetes Treatment Before CMS
This article was originally published in The Gray Sheet
CMS should evaluate individually the various techniques it categorizes as outpatient intravenous insulin therapy before deciding which, if any, it will cover, say two commenters to the Medicare agency
You may also be interested in...
Evidence supporting outpatient intravenous insulin therapy as an adjunctive diabetes treatment is insufficient to justify Medicare coverage, CMS says in a Sept. 25 proposed decision memo
Outpatient intravenous insulin treatment could gain traction as an adjunctive diabetes therapy under a CMS coverage analysis initiated March 25
Asking whether FDA’s decision to allow emergency use of two old anti-malarial drugs was ‘political’ misses the point. The issue already was political, and FDA’s action may well be the best way to keep some measure of federal control on supplies of a drug with important other uses.